| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 158.6 | 124.7 | 119.5 |
| Other income | 2.6 | 0.8 | 0.8 |
| Total income | 161.3 | 125.5 | 120.3 |
| Profit before exceptional items & tax | -7.9 | -13.6 | -15.7 |
| Exceptional items | 0.0 | 2.1 | 0.0 |
| Profit before tax | -7.9 | -15.7 | -15.7 |
| Net profit | -7.5 | -15.5 | -16.3 |
| Operating margin | -4.9% | -12.5% | -13.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +32.70% |
|---|
NSE results filing, NSE: ASTEC. Figures extracted from the filing.
Astec Lifesciences Ltd: key numbers
- Share price
- ₹748.20
- Market cap
- ₹1,667 Cr
- Revenue (annual)
- ₹448.1 Cr
- Net profit (annual)
- ₹-80.92 Cr
- P/E (TTM)
- -25.0×Sector 36.8×
- Promoter holding
- 71.96%-0.01% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Astec Lifesciences Ltd
All →Astec Lifesciences Price Movement Clarification
Astec LifeSciences responded to an NSE surveillance query on volume spurt. The company confirmed no developments requiring mandatory disclosure under LODR or PIT Regulations.
Astec Lifesciences Debt & Borrowing: ₹25 Cr
Astec LifeSciences Limited has confirmed the timely payment of the maturity amount for its commercial paper. The redemption amount totals ₹25 Crore.
- Value
- ₹25.00 Cr
Astec Lifesciences Price Movement Clarification
Astec LifeSciences replied to an NSE volume-spike surveillance notice, confirming full disclosure compliance. No undisclosed developments exist under Listing or PIT Regulations.
Astec Lifesciences Debt & Borrowing: ₹75 Cr
Astec LifeSciences has set record dates for the redemption of three Commercial Paper series, with each series maturing at a value of ₹25 Crore.
- Value
- ₹75.00 Cr
Astec Lifesciences Annual General Meeting
Astec LifeSciences held its 32nd AGM on July 31, 2026. The meeting approved financial statements, director re-appointment, and cost auditor remuneration.
Astec Lifesciences Results Update
Astec LifeSciences announced its Q1 FY27 financial results, reporting total income of ₹84.3 crore and an EBITDA of ₹0.1 crore.